Unitaid to provide funding for Gilead HIV prevention drug in South Africa, Zambia

Taking stock of the drug industry, from the lab to the medicine chest

January 14, 2026 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Nardus Engelbrecht/AP STAT+ | Unitaid will provide funds for South Africa and Zambia to widen access to Gilead's HIV prevention drug Unitaid will work with local health ministries and community groups to facilitate distribution of lenacapavir to vulnerable populations By Ed Silverman STAT+ | On Day 3 of JPM, pharma threads a needle with the White House, and Novo Nordisk has an eye on M&A Day 3 of the JP Morgan Healthcare Conference newsletter has news and updates from Novo Nordisk, Sanofi, Pfizer, Bristol Meyers Squibb, and other companies. By Matthew Herper, Elaine Chen, Adam Feuerstein, and Allison DeAngelis STAT+ | Should Medicare automatically pay for medical devices that the FDA deems 'breakthrough'? As Congress considers automatic Medicare coverage for 'breakthrough' devices, experts caution that it could drive up costs without improving patient outcomes. By Katie Palmer Live from JPM 2026, a sit-down with Novo Nordisk's CEO and VC Bob Nelsen In a special live taping at the JP Morgan conference, the hosts sit down with ARCH Venture Partners' Bob Nelsen and Novo Nordisk's CEO. By Allison DeAngelis, Adam Feuerstein, and Elaine Chen Watch: At JPM, former drug regulator Richard Pazdur rings the alarm about politics at FDA FDA veteran Richard Pazdur made his first public remarks since his abrupt FDA departure at a STAT JPM 2026 event. Watch the full video here. By STAT Staff

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2026, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser